Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx Eyes $1.5M Financing Round for Clinical Trials of Nucleosome-based Tests

NEW YORK (GenomeWeb News) – Cancer diagnostics firm VolitionRx has raised $595,000 toward a targeted $1.5 million round, it said in a document filed with the US Securities and Exchange Commission.

In an e-mail to GenomeWeb Daily News, a company spokesperson said the funding will go toward ongoing trials for its NuQ technology, including clinical trials announced late last month with Hvidovre Hospital in Denmark for colorectal cancer.

Investors in the round consisted of individual investors. The company has raised a total of $1.5 million in 2013 and about $6.0 million since its founding in late 2010.

In May 2012, the Singapore-based firm raised $1.2 million to fund clinical trials for its first NuQ test kits, which are blood-based diagnostic tests based on VolitionRx’s Nucleosomics technology. The technology detects and measures nucleosomes in the bloodstream.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.